AbbVie Inc

AbbVie’s $2B licensing deal with Gubra for weight‑loss candidate ABBV‑295, its diversified immunology‑oncology portfolio, and analysts’ focus on AI‑driven competition show how the pharma giant’s strategic partnerships and portfolio depth may secure …

AbbVie invests $380 million to build two new U.S. API facilities in North Chicago, boosting domestic production of neuroscience and obesity drugs, cutting costs and strengthening supply‑chain resilience.

AbbVie declares a $1.73 quarterly dividend, signaling cash‑flow strength and steady earnings growth in immunology and dermatology while expanding its biotech pipeline for future gains.

AbbVie’s Medicaid pricing deal, U.S. R&D investment and exclusive antibody license set a new strategy for U.S. market dominance amid patent cliffs and fierce competition.

AbbVie faces a 12% Humira decline but plans 12‑year growth via biosimilar‑ready market‑access, new indications, RWE deals, and precision‑medicine M&A.

AbbVie’s Q4 earnings dip amid heavy R&D spend—no Revolution Medicines deal—signals a long‑term focus on immunology, oncology, and new biologics, reshaping 2025 forecasts and patient care strategies.

AbbVie’s JPMC strategy: high‑margin neuromuscular growth, value‑based pricing, and digital platforms to boost access, reduce costs, and outpace the 14% CAGR market.

AbbVie’s Q3 miss yet raised guidance, dividend hike, and drug‑price talks show how a pharma giant balances earnings, returns and regulation.

AbbVie’s recent analyst upgrades spotlight its strong pipeline, solid cash flow and disciplined capital allocation—making the biotech stock a compelling, risk‑adjusted growth opportunity.

AbbVie refines its chronic inflammation partnership with OSE Immunotherapeutics, shifting Phase‑1 duties and boosting ABBV‑230’s development while retaining long‑term equity and regulatory control.